MARKET

DTCFF

DTCFF

Defence Therapeu
OTCMQB
0.255
NaN%
Closed 09:30 10/19 EDT
OPEN
--
PREV CLOSE
0.250
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.779
52 WEEK LOW
0.243
MARKET CAP
14.60M
P/E (TTM)
-3.1798
1D
5D
1M
3M
1Y
5Y
1D
Defence Therapeutics’ Accum Platform Takes Spotlight at World ADC San Diego 2026
TipRanks · 18h ago
Weekly Report: what happened at DTCFF last week (1012-1016)?
Weekly Report · 19h ago
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Newsfile · 23h ago
Weekly Report: what happened at DTCFF last week (1005-1009)?
Weekly Report · 10/12 10:34
Weekly Report: what happened at DTCFF last week (0928-1002)?
Weekly Report · 10/05 10:34
Defence Therapeutics to Spotlight Accum Platform at World ADC San Diego
TipRanks · 10/01 11:38
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Newsfile · 10/01 07:15
Defence Therapeutics Bolsters Board With Veteran Finance Executive Sherry Aulin
TipRanks · 09/29 12:14
More
About DTCFF
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Webull offers Defence Therapeutics Inc stock information, including OTCMQB: DTCFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTCFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTCFF stock methods without spending real money on the virtual paper trading platform.